1-(benzo[d]oxazol-2-carbonyl)-3-(6-(pentyloxy)pyridin-3-yl)thiourea | 870149-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 1-(benzo[d]oxazol-2-carbonyl)-3-(6-(pentyloxy)pyridin-3-yl)thiourea
• 英文别名: 1-(benzo[d]oxazole-2-carbonyl)-3-(6-(pentyloxy)pyridin-3-yl)thiourea；N-[(6-pentoxypyridin-3-yl)carbamothioyl]-1,3-benzoxazole-2-carboxamide
• CAS: 870149-66-9
• 化学式: C₁₉H₂₀N₄O₃S
• 分子量: 384.459
• InChiKey: ROUVZIXYFDBANN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
  申请人：Phadke Avinash

  公开号：US20060025416A1

  公开（公告）日：2006-02-02

  The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A 1 , A 2 , R 1 , R 2 , V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.

  该发明提供了化合物和药用可接受的盐的公式I，其中变量A1、A2、R1、R2、V、W、X、Y和Z在此处定义。本文描述了公式I的某些化合物具有强效的抗病毒活性。该发明特别提供了公式I的化合物，这些化合物是对丙型肝炎病毒复制具有强效和/或选择性抑制作用的。该发明还提供了含有一个或多个公式I化合物、或这些化合物的盐、溶剂合物或酰化前药，以及一个或多个药用可接受的载体、辅料或稀释剂的药物组合物。该发明还包括通过向患有某些传染病的患者投与有效量的公式I化合物来减轻疾病或紊乱的症状或迹象的治疗方法。这些传染病包括病毒感染，特别是HCV感染。该发明特别包括治疗患有传染病的人类患者的方法，但也包括治疗其他动物，包括家畜和驯养的伴侣动物，患有传染病的方法。治疗方法包括单独使用公式I化合物作为活性剂或与一个或多个其他治疗剂联合使用公式I化合物。
• SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20090023730A1

  公开（公告）日：2009-01-22

  The invention provides compounds and pharmaceutically acceptable salts of Formula I wherein the variables A 1 , A 2 , R 1 , R 2 , V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.

  本发明提供了式I的化合物和药学上可接受的盐，其中变量A1、A2、R1、R2、V、W、X、Y和Z在此定义。本文所描述的式I的某些化合物具有强效的抗病毒活性。本发明特别提供了式I的化合物，它们是强效和/或选择性的丙型肝炎病毒复制抑制剂。本发明还提供了含有式I的一个或多个化合物，或这些化合物的盐、溶剂合物或酰化前药的药物组合物，以及一个或多个药学上可接受的载体、赋形剂或稀释剂的制剂。本发明还包括通过向这些患者投与有效量的式I的化合物来治疗患有某些传染性疾病的患者的方法，以减轻疾病或失调的症状。这些传染性疾病包括病毒感染，特别是丙型肝炎病毒感染。本发明特别包括治疗患有传染性疾病的人类患者的方法，但也包括治疗其他动物，包括牲畜和家养伴侣动物，患有传染性疾病的方法。治疗方法包括将式I的化合物作为单一活性剂或将式I的化合物与一个或多个其他治疗剂联合使用。
• US7365068B2
  申请人：——

  公开号：US7365068B2

  公开（公告）日：2008-04-29
• US7767706B2
  申请人：——

  公开号：US7767706B2

  公开（公告）日：2010-08-03
• [EN] SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION<br/>[FR] ARYLE THIOUREES SUBSTITUES ET COMPOSES ASSOCIES; INHIBITEURS DE LA REPLICATION VIRALE
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2006083271A2

  公开（公告）日：2006-08-10

  [EN] The invention provides compounds and pharmaceutically acceptable salts of Formula (I) wherein the variables A₁, A₂, R₁, R₂, V, W, X, Y, and Z are defined herein. Certain compounds of Formula (I) described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula (I) that are potent and/ or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula (I), or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula (I) as a single active agent or administering a compound of Formula (I) in combination with on or more other therapeutic agent.
  [FR] La présente invention a trait à des composés et des sels pharmaceutiquement acceptables de formule (I), dans laquelle: les variables A₁, A₂, R₁, R₂, V, W, X, Y et Z sont tels que définis dans la description. Certains composés de formule (I) de l'invention possèdent une activité antivirale puissante. L'invention a trait particulièrement à des composés de formule (I) qui sont des inhibiteurs puissants et/ou sélectifs de la réplication du virus de l'hépatite C. L'invention a également trait à des compositions pharmaceutiques contenant un ou des compositions de formule (I), ou un sel, solvate, ou prodrogue acylé de tels composés, et un ou des supports, excipients, ou diluants pharmaceutiquement acceptables. L'invention a trait en outre à des procédés de traitement de patients souffrant de certaines maladies infectieuses par l'administration à de tels patients d'une quantité d'un composé de formule (I) efficace pour la réduction de signes ou symptômes de la maladie ou du trouble. Ces maladies infectieuses comprennent des infections virales, notamment des infections par le virus de l'hépatite C. L'invention concerne particulièrement des procédés de traitement de patients humains souffrant d'une maladie infectieuse, mais ne concerne pas des procédés de traitement d'autres animaux, comprenant des animaux d'élevage et des animaux de compagnie domestiqués, souffrant d'une maladie infectieuse. Les procédés comprennent l'administration d'un composé de formule (I) sous forme d'un agent unique ou l'administration d'un composé de formule (I) en combinaison avec une ou plusieurs autre(s) agent(s) thérapeutiques.